Nicholas A. Crossland, DVM, DACVP
Assistant Professor, Pathology & Laboratory Medicine
Biography
Dr. Crossland is a board certified Veterinary Anatomic Pathologist. He shares a dual appointment as an Assistant Professor in the Department of Pathology and Laboratory Medicine at Chobanian and Avedisian School of Medicine and an Investigator at the NEIDL where he directs the NEIDL Comparative Pathology Laboratory (NCPL).
His lab aims to elucidate pathogen-host interactions of highly pathogenic microbes. His lab complements classic pathology approaches with cutting edge technologies such as high throughput tissue staining, spatial transcriptomics and quantitative image analysis. This approach enables the discovery of biological pathways driving and preventing disease. At the translational level, we use our expertise to evaluate the efficacy of medical counter measures with the ultimate goal of alleviating and preventing human suffering.
His lab mentors both MS and PhD students that have their sites on pursuing a career in translational research. He is actively exploring collaborative opportunities with other BUMC faculty members to push the outputs achieved from tissue based assays to drive discovery and enhance our understanding of host-pathogen interactions.
Other Positions
- Faculty, National Emerging Infectious Disease Lab, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Education
- Kansas State University, DVM
- Kansas State University, BS
Publications
- Published on 4/2/2024
Nambulli S, Escriou N, Rennick LJ, Demers MJ, Tilston-Lunel NL, McElroy AK, Barbeau DJ, Crossland NA, Hoehl RM, Schrauf S, White AG, Borish HJ, Tomko JA, Frye LJ, Scanga CA, Flynn JL, Martin A, Gerke C, Hartman AL, Duprex WP. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease. J Virol. 2024 Apr 02; e0176223. PMID: 38563762.
Read at: PubMed - Published on 3/10/2024
Yabaji SM, Zhernovkov V, Araveti PB, Lata S, Rukhlenko OS, Abdullatif SA, Alekseev Y, Ma Q, Dayama G, Lau NC, Bishai WR, Crossland NA, Campbell JD, Kholodenko BN, Gimelbrant AA, Kobzik L, Kramnik I. Myc Dysregulation in Activated Macrophages Initiates Iron-Mediated Lipid Peroxidation that Fuels Type I Interferon and Compromises TB Resistance. bioRxiv. 2024 Mar 10. PMID: 38496444.
Read at: PubMed - Published on 3/8/2024
Kenney D, O'Connell AK, Tseng AE, Turcinovic J, Sheehan ML, Nitido AD, Montanaro P, Gertje HP, Ericsson M, Connor JH, Vrbanac V, Crossland NA, Harly C, Balazs AB, Douam F. Resolution of SARS-CoV-2 infection in human lung tissues is driven by extravascular CD163+ monocytes. bioRxiv. 2024 Mar 08. PMID: 38496468.
Read at: PubMed - Published on 11/29/2023
Crossland NA, Beck S, Tan WY, Lo M, Mason JB, Zhang C, Guo W, Crott JW. Fecal microbiota transplanted from old mice promotes more colonic inflammation, proliferation, and tumor formation in azoxymethane-treated A/J mice than microbiota originating from young mice. Gut Microbes. 2023 Dec; 15(2):2288187. PMID: 38031252.
Read at: PubMed - Published on 11/13/2023
Fletcher P, Feldmann F, Takada A, Crossland NA, Hume AJ, Albariño C, Kemenesi G, Feldmann H, Mühlberger E, Marzi A. Pathogenicity of Lloviu and Bombali Viruses in Type I Interferon Receptor Knockout Mice. J Infect Dis. 2023 Nov 13; 228(Supplement_7):S548-S553. PMID: 37352146.
Read at: PubMed - Published on 9/21/2023
Kehrer T, Cupic A, Ye C, Yildiz S, Bouhaddou M, Crossland NA, Barrall EA, Cohen P, Tseng A, Çagatay T, Rathnasinghe R, Flores D, Jangra S, Alam F, Mena I, Aslam S, Saqi A, Rutkowska M, Ummadi MR, Pisanelli G, Richardson RB, Veit EC, Fabius JM, Soucheray M, Polacco BJ, Ak B, Marin A, Evans MJ, Swaney DL, Gonzalez-Reiche AS, Sordillo EM, van Bakel H, Simon V, Zuliani-Alvarez L, Fontoura BMA, Rosenberg BR, Krogan NJ, Martinez-Sobrido L, García-Sastre A, Miorin L. Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis. Cell Host Microbe. 2023 Oct 11; 31(10):1668-1684.e12. PMID: 37738983.
Read at: PubMed - Published on 9/14/2023
Lyon De Ana C, Shenoy AT, Barker KA, Arafa EI, Etesami NS, Korkmaz FT, Soucy AM, Breen MP, Martin IMC, Tilton BR, Devarajan P, Crossland NA, Pihl RMF, Goltry WN, Belkina AC, Jones MR, Quinton LJ, Mizgerd JP. GL7 ligand expression defines a novel subset of CD4+ TRM cells in lungs recovered from pneumococcus. Mucosal Immunol. 2023 Oct; 16(5):699-710. PMID: 37604254.
Read at: PubMed - Published on 6/16/2023
Liu Y, Cafiero TR, Park D, Biswas A, Winer BY, Cho CH, Bram Y, Chandar V, Connell AKO, Gertje HP, Crossland N, Schwartz RE, Ploss A. Targeted viral adaptation generates a simian-tropic hepatitis B virus that infects marmoset cells. Nat Commun. 2023 Jun 16; 14(1):3582. PMID: 37328459.
Read at: PubMed - Published on 5/12/2023
Tseng AE, Carossino M, Gertje HP, O'Connell AK, Gummuluru S, Kolachalama VB, Balasuriya UBR, Connor JH, Bennett RS, Liu DX, Hensley LE, Crossland NA. Hepatic proinflammatory myeloid phenotypes are a hallmark of Ebola virus Kikwit pathogenesis in rhesus monkeys. Vet Pathol. 2023 Jul; 60(4):473-487. PMID: 37170900.
Read at: PubMed - Published on 4/10/2023
Chen DY, Turcinovic J, Feng S, Kenney DJ, Chin CV, Choudhary MC, Conway HL, Semaan M, Close BJ, Tavares AH, Seitz S, Khan N, Kapell S, Crossland NA, Li JZ, Douam F, Baker SC, Connor JH, Saeed M. Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. iScience. 2023 May 19; 26(5):106634. PMID: 37095858.
Read at: PubMed
View 36 more publications: View full profile at BUMC